蛋白质结合分析市场 - 全球产业规模、份额、趋势、机会及预测（按技术、产品/服务、最终用户、地区和竞争格局划分，2021-2031年）

全球蛋白质结合分析市场预计将从 2025 年的 5.8065 亿美元成长到 2031 年的 10.6336 亿美元，复合年增长率为 10.61%。

这些检测方法是专门的分析程序，用于量化药物分子与血浆蛋白的可逆结合，这是确定具有治疗活性的游离药物比例的关键步骤。该市场的成长主要源于药物发现早期阶段对生物利用度和毒性特征的必要评估，这项策略旨在降低后期研发阶段的失败率。此外，对药物创新的巨额投资也进一步推动了这一成长。根据欧洲製药工业协会联合会（EFPIA）预测，到2024年，欧洲以研发为基础的製药业预计将在研发方面投入约550亿欧元，这笔巨额资本投资也保证了对这些临床前服务的需求。

儘管市场成长势头强劲，但由于先进的平衡透析和表面等离子共振技术的复杂性和高成本，该市场仍面临显着的挑战。精确测量蛋白质交互作用需要专用设备和高技能人员，这造成了财务和营运负担，可能阻碍技术的广泛应用。对于小规模的生技公司而言，这个问题尤其突出，因为这些先进检测技术的固定成本可能超过其可用资源，并阻碍其融入标准工作流程。

市场驱动因素

製药和生物技术领域研发投入的不断增长是市场扩张的主要催化剂，直接推动了候选药物研发失败率，越来越多的资金被投入ADME（吸收、分布、代谢和排泄）分析中，该分析用于评估化合物与血浆蛋白（如白蛋白和α1-酸性Glico）的相互作用。这笔巨额资金投入使实验室能够获得必要的试剂并检验通讯协定。例如，美国药品研究与製造商协会（PhRMA）在2024年9月发布的一项调查报告显示，其成员公司将在2023年投入创纪录的1035亿美元用于研发，这凸显了生物分析研究领域获得的巨额资金。

此外，慢性病和感染疾病的日益增多迫使製药业加快药物研发步伐，导致所需的结合研究数量激增。美国癌症协会预测，到2024年1月，美国新增癌症病例将首次超过200万例，显示患者对快速创新治疗方法和精准给药的需求日益增长。这种压力推动了检测服务提供者对检测处理容量要求不断提高，美国食品药物管理局（FDA）2024年的报告也印证了这个趋势。报告指出，去年有55种新型疗法核准，这反映了这些检测流程的持续成功和重要性。

市场挑战

全球蛋白质结合分析市场面临许多挑战，例如平衡透析和表面等离子共振等先进技术的技术复杂性和高昂的营运成本。实施这些先进的分析方法需要对设备进行大量资本投入，并招募高技能人员以确保数据解读的准确性。对于中小型生物技术公司（创新流程中的关键环节）而言，这些固定成本往往超出其可用资源，限制了它们内部建立重要检测能力，从而有效地抑制了市场规模的成长和渗透率的提高。

中小规模市场参与企业流动性有限，限制了它们投资资本密集型设备的能力，这加剧了上述挑战。根据英国生物产业协会（BIA）2024年的数据，英国生技产业已资金筹措了35亿英镑，但首次股票公开发行（IPO）却连续第二年完全停滞。资本结构失衡，资金集中在少数企业手中，且缺乏公开市场退出管道，这显着降低了更广泛客户群的购买力；此外，蛋白质偶联技术的高成本也对资金紧张的开发商构成了重大障碍。

市场趋势

生物製剂和标靶蛋白降解剂结合分析方法的扩展正在从根本上改变市场格局，因为与传统小分子药物相比，这些复杂的药物需要高度专业的检测通讯协定。研发人员越来越关注大分子相互作用的评估，包括胜肽和寡核苷酸，这需要复杂的检测方法才能准确评估结合动力学和亲和性。药明康德2024年3月发布的报告清晰地展现了这种结构性转变，该公司TIDES业务（肽和寡核苷酸）的收入同比增长64.4%，反映了行业正迅速向这些复杂的治疗领域转型。

随着技术多元化的发展，将结合研究外包给受託研究机构(CRO) 的趋势日益明显，以此来规避自行建构先进检测平台的高昂资本投入。随着蛋白质交互作用的测量变得日益复杂，製药公司正利用 CRO 的专业基础设施来维持高通量检测能力，而无需承担购买专用设备的固定成本。这种对外部伙伴关係模式的依赖正在推动服务业的显着成长。 Icon PLC 截至 2024 年 2 月的财年报告显示，其年收入达 81.2 亿美元（年增 4.9%），这主要得益于对外包研发服务的持续需求。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章：全球蛋白质结合分析市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 透过技术（平衡透析、亲和性和电泳、超过滤、超速离心、表面等离子体共振等）
  • 依产品/服务分类（仪器、试剂盒/试剂、服务）
  • 按最终用户（製药/生物技术公司、契约製造组织 (CRO) 及其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美蛋白质结合测定市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲蛋白质结合分析市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区蛋白质结合分析市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲蛋白质结合测定市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲蛋白质结合测定市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球蛋白质结合分析市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Merck KGaA
• Thermo Fisher Scientific Inc.
• Sovicell
• Cyprotex（Evotec AG）
• Bioduro. LLC
• GE HealthCare Technologies Inc.
• Beckman Coulter, Inc.
• Sartorius AG
• Bio-Rad Laboratories, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Protein Binding Assays Market is projected to expand from USD 580.65 Million in 2025 to USD 1063.36 Million by 2031, reflecting a compound annual growth rate of 10.61%. These assays are specialized analytical procedures designed to quantify the reversible association between drug molecules and plasma proteins, a critical step in determining the free fraction of a drug available for therapeutic action. The market is primarily driven by the essential need to evaluate bioavailability and toxicity profiles during the early stages of drug discovery, a strategy aimed at reducing attrition rates in later development phases. This growth is further supported by significant financial investments in pharmaceutical innovation; according to the European Federation of Pharmaceutical Industries and Associations, the research-based pharmaceutical industry invested an estimated €55,000 million in R&D in Europe during 2024, highlighting the substantial capital ensuring the demand for these preclinical services.

Despite this strong growth trajectory, the market faces a notable challenge regarding the technical complexity and high costs linked to advanced equilibrium dialysis and surface plasmon resonance technologies. The necessity for specialized equipment and highly skilled personnel to accurately measure protein interactions creates financial and operational burdens that can hinder broader adoption. This is particularly problematic for smaller biotechnology firms, where the high fixed costs of these sophisticated testing capabilities may exceed available resources, thereby impeding their integration into standard workflows.

Market Driver

The escalation of R&D investments within the pharmaceutical and biotechnology sectors acts as a primary catalyst for market expansion, directly facilitating the rigorous preclinical evaluations necessary for new drug candidates. As developers aim to minimize attrition, financial resources are increasingly directed toward ADME profiling to assess compound interactions with plasma proteins like albumin and alpha-1-acid glycoprotein. This significant capital commitment ensures laboratories can secure necessary reagents and validate protocols; for instance, the Pharmaceutical Research and Manufacturers of America reported in their September 2024 survey that member companies invested a record $103.5 billion in R&D during 2023, underscoring the massive funding available for these bioanalytical investigations.

Furthermore, the rising prevalence of chronic and infectious diseases forces the industry to accelerate drug discovery efforts, thereby increasing the volume of required binding studies. The American Cancer Society projected in January 2024 that new cancer cases in the United States would exceed 2 million for the first time, signaling a growing patient need that necessitates rapid therapeutic innovation and precise dosing determination. This pressure results in higher throughput requirements for assay providers, a trend validated by the U.S. Food and Drug Administration's 2024 report, which noted the approval of 55 novel therapeutics in the previous year, reflecting the sustained output and importance of these testing workflows.

Market Challenge

The Global Protein Binding Assays Market faces significant barriers due to the technical complexity and substantial operational costs associated with advanced technologies such as equilibrium dialysis and surface plasmon resonance. Implementing these sophisticated analytical methods requires major capital expenditure on instrumentation and the hiring of highly skilled personnel to ensure accurate data interpretation. For smaller biotechnology firms, which represent a crucial segment of the innovation pipeline, these fixed costs often surpass available resources, restricting their ability to internalize critical testing capabilities and effectively capping the market's volume growth and adoption rates.

This challenge is further exacerbated by the restricted liquidity available to smaller market participants, limiting their capacity to invest in capital-intensive equipment. According to the BioIndustry Association in 2024, while the UK biotech sector raised £3.5 billion in financing, there was a complete dormancy of initial public offerings (IPOs) for the second consecutive year. This capitalization imbalance, where funding is concentrated among fewer players and public exit routes are closed, severely reduces the purchasing power of the broader client base, making the high cost of protein binding technologies a primary friction point for financially constrained developers.

Market Trends

The market landscape is being fundamentally altered by the expansion of binding assays for biologics and targeted protein degraders, as these complex modalities demand highly specialized testing protocols compared to traditional small molecules. Developers are increasingly focusing on evaluating large molecule interactions, such as those involving peptides and oligonucleotides, which requires advanced assay formats to accurately characterize binding kinetics and affinity. This structural shift is highlighted by WuXi AppTec's March 2024 report, which noted that revenue from their TIDES business (peptides and oligonucleotides) grew by 64.4% year-over-year, reflecting the industry's rapid pivot toward these complex therapeutic areas.

Concurrent with this technical diversification is a growing trend of outsourcing binding studies to contract research organizations (CROs) as a strategy to bypass the high capital barriers of internalizing advanced assay platforms. As the complexity of measuring protein interactions increases, pharmaceutical companies are leveraging the specialized infrastructure of CROs to maintain high-throughput capabilities without the fixed costs of specialized instrumentation. This reliance on external partnership models is driving significant growth in the service sector, evidenced by Icon PLC's February 2024 report, which announced full-year revenue of $8.12 billion, a 4.9% increase over the prior year fueled by sustained demand for externalized development services.

Key Market Players

• Merck KGaA
• Thermo Fisher Scientific Inc.
• Sovicell
• Cyprotex (Evotec A.G.)
• Bioduro. LLC
• GE HealthCare Technologies Inc.
• Beckman Coulter, Inc.
• Sartorius AG
• Bio-Rad Laboratories, Inc.

Report Scope

In this report, the Global Protein Binding Assays Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Protein Binding Assays Market, By Technology

• Equilibrium Dialysis
• Affinity Electrophoresis
• Ultrafiltration
• Ultracentrifugation
• Surface Plasmon Resonance
• Others

Protein Binding Assays Market, By Product and Services

• Instrument
• Kits and Reagents
• Services

Protein Binding Assays Market, By End-Users

• Pharmaceutical and Biotechnology Companies
• Contract Manufacturing Organizations (CROs)
• Others

Protein Binding Assays Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Protein Binding Assays Market.

Available Customizations:

Global Protein Binding Assays Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Protein Binding Assays Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Equilibrium Dialysis, Affinity Electrophoresis, Ultrafiltration, Ultracentrifugation, Surface Plasmon Resonance, Others)
  • 5.2.2. By Product and Services (Instrument, Kits and Reagents, Services)
  • 5.2.3. By End-Users (Pharmaceutical and Biotechnology Companies, Contract Manufacturing Organizations (CROs), Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Protein Binding Assays Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Product and Services
  • 6.2.3. By End-Users
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Protein Binding Assays Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Product and Services
      • 6.3.1.2.3. By End-Users
  • 6.3.2. Canada Protein Binding Assays Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Product and Services
      • 6.3.2.2.3. By End-Users
  • 6.3.3. Mexico Protein Binding Assays Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Product and Services
      • 6.3.3.2.3. By End-Users

7. Europe Protein Binding Assays Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Product and Services
  • 7.2.3. By End-Users
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Protein Binding Assays Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Product and Services
      • 7.3.1.2.3. By End-Users
  • 7.3.2. France Protein Binding Assays Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Product and Services
      • 7.3.2.2.3. By End-Users
  • 7.3.3. United Kingdom Protein Binding Assays Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Product and Services
      • 7.3.3.2.3. By End-Users
  • 7.3.4. Italy Protein Binding Assays Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Product and Services
      • 7.3.4.2.3. By End-Users
  • 7.3.5. Spain Protein Binding Assays Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Product and Services
      • 7.3.5.2.3. By End-Users

8. Asia Pacific Protein Binding Assays Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Product and Services
  • 8.2.3. By End-Users
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Protein Binding Assays Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Product and Services
      • 8.3.1.2.3. By End-Users
  • 8.3.2. India Protein Binding Assays Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Product and Services
      • 8.3.2.2.3. By End-Users
  • 8.3.3. Japan Protein Binding Assays Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Product and Services
      • 8.3.3.2.3. By End-Users
  • 8.3.4. South Korea Protein Binding Assays Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Product and Services
      • 8.3.4.2.3. By End-Users
  • 8.3.5. Australia Protein Binding Assays Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Product and Services
      • 8.3.5.2.3. By End-Users

9. Middle East & Africa Protein Binding Assays Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Product and Services
  • 9.2.3. By End-Users
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Protein Binding Assays Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Product and Services
      • 9.3.1.2.3. By End-Users
  • 9.3.2. UAE Protein Binding Assays Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Product and Services
      • 9.3.2.2.3. By End-Users
  • 9.3.3. South Africa Protein Binding Assays Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Product and Services
      • 9.3.3.2.3. By End-Users

10. South America Protein Binding Assays Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Product and Services
  • 10.2.3. By End-Users
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Protein Binding Assays Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Product and Services
      • 10.3.1.2.3. By End-Users
  • 10.3.2. Colombia Protein Binding Assays Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Product and Services
      • 10.3.2.2.3. By End-Users
  • 10.3.3. Argentina Protein Binding Assays Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Product and Services
      • 10.3.3.2.3. By End-Users

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Protein Binding Assays Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Merck KGaA
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Thermo Fisher Scientific Inc.
• 15.3. Sovicell
• 15.4. Cyprotex (Evotec A.G.)
• 15.5. Bioduro. LLC
• 15.6. GE HealthCare Technologies Inc.
• 15.7. Beckman Coulter, Inc.
• 15.8. Sartorius AG
• 15.9. Bio-Rad Laboratories, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer